Ypsomed Holding AG (0QLQ)
London Stock Exchange · UK · prices in GBP · close of 27 Oct 2026
Key indicators
| Last close | GBP 388.60 |
|---|---|
| 52-week range | 263.50 – 417.00 |
| Return, 1 month / 3 months | +8.3% / −0.9% |
| Return, 1 year / 3 years | +22.6% / +57.0% |
| Trend | Uptrend |
| RSI (14) | 63 |
| Volatility (1 year) | 28.9% |
| Worst drawdown (1 year) | -23.0% |
| Average daily value traded | 0.73M GBP |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Ypsomed Holding AG makes injection and infusion systems that patients use to administer medicines themselves at home. The company produces pen injectors, autoinjectors and insulin pumps, and supplies them to pharmaceutical and biotechnology firms that fill them with their own drugs, as well as to people managing chronic conditions such as diabetes. Ypsomed is based in Burgdorf, Switzerland, and its devices are used in markets around the world.
On this site Ypsomed Holding AG appears as a stock on the London Stock Exchange (UK), code 0QLQ, with prices in pounds sterling (GBP). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Ypsomed Holding AG (0QLQ) trades on the London Stock Exchange in UK. It last closed at GBP 388.60 on 27 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 687 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 22.6% and over the last three months it fell 0.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 81 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.1% | ||
| From 52-week high | -6.3% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -0.9% | ||
| 6-month return | 39.1% | ||
| 12-month return, skipping the last month | 13.2% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.0% | ||
| Liquidity | 50 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.73M GBP | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.0% |
|---|---|
| 1 month | +8.3% |
| 3 months | −0.9% |
| 6 months | +39.1% |
| 1 year | +22.6% |
| 3 years | +57.0% |
| 5 years | +157.5% |
Signals
| 50-day / 200-day average | 377.63 / 337.74 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 6.54 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jul 2026 | GBX 0.0270 |
| 4 Jul 2025 | GBX 0.0110 |
| 1 Jul 2024 | GBX 0.0100 |
| 3 Jul 2023 | GBX 0.0065 |
| 4 Jul 2022 | GBX 0.0030 |
| 7 Jul 2021 | GBX 0.0058 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.